Spyre Therapeutics announced today that SPY001, an extended half-life α4β7, showed a 40% clinical remission rate at 12 weeks in moderate-to-severe UC

BiotechTV - News - Spyre Therapeutics announced today that SPY001, an extended half-life α4β7, showed a 40% clinical remission rate at 12 weeks in moderate-to-severe UC